| Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy BJCKK Amrita Basu, Ganesan Ramamoorthi, Gabriella Albert, Corey Gallen ... Frontiers in Immunology, 2021 | 233 | 2021 |
| Immunotherapy in breast cancer: Current status and future directions A Basu, G Ramamoorthi, Y Jia, J Faughn, D Wiener, S Awshah, ... Advances in cancer research 143, 295-349, 2019 | 115 | 2019 |
| Sequential anti-PD1 therapy following dendritic cell vaccination improves survival in a HER2 mammary carcinoma model and identifies a critical role for CD4 T cells in mediating … KN Kodumudi, G Ramamoorthi, C Snyder, A Basu, Y Jia, S Awshah, ... Frontiers in immunology 10, 1939, 2019 | 44 | 2019 |
| Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway Y Jia, KN Kodumudi, G Ramamoorthi, A Basu, C Snyder, D Wiener, ... Molecular Therapy 29 (4), 1541-1556, 2021 | 40 | 2021 |
| Oncodriver inhibition and CD4+ Th1 cytokines cooperate through Stat1 activation to induce tumor senescence and apoptosis in HER2+ and triple negative breast cancer … C Rosemblit, J Datta, L Lowenfeld, S Xu, A Basu, K Kodumudi, D Wiener, ... Oncotarget 9 (33), 23058, 2018 | 35 | 2018 |
| Spatial learning and memory in male mice with altered growth hormone action A Basu, HG McFarlane, JJ Kopchick Hormones and Behavior 93, 18-30, 2017 | 33 | 2017 |
| Disseminated cancer cells in breast cancer: Mechanism of dissemination and dormancy and emerging insights on therapeutic opportunities G Ramamoorthi, K Kodumudi, C Gallen, NN Zachariah, A Basu, G Albert, ... Seminars in cancer biology 78, 78-89, 2022 | 30 | 2022 |
| Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma G Ramamoorthi, K Kodumudi, C Snyder, P Grover, H Zhang, MI Greene, ... Journal for Immunotherapy of Cancer 10 (6), 2022 | 14 | 2022 |
| Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4+ Th1 Responses and Potential Use as a Cancer Vaccine A Basu, GK Albert, S Awshah, J Datta, KN Kodumudi, C Gallen, A Beyer, ... Cancer immunology research 10 (1), 108-125, 2022 | 14 | 2022 |
| GH in the central nervous system: Lessons from the growth hormone receptor knockout mouse ES Gosney, A Jara, A Basu, JJ Kopchick Open Endocrinology Journal 6 (1), 34-41, 2012 | 11 | 2012 |
| Intercepting premalignant, preinvasive breast lesions through vaccination NN Zachariah, A Basu, N Gautam, G Ramamoorthi, KN Kodumudi, ... Frontiers in Immunology 12, 786286, 2021 | 9 | 2021 |
| Relevance of lymphocyte proliferation to PHA in severe combined immunodeficiency (SCID) and T cell lymphopenia RS Abraham, A Basu, JR Heimall, E Dunn, A Yip, M Kapadia, N Kapoor, ... Clinical Immunology 261, 109942, 2024 | 4 | 2024 |
| Refractory, fatal autoimmune hemolytic anemia due to ineffective thymic-derived T-cell reconstitution following allogeneic hematopoietic cell transplantation for hypomorphic … JR Yonkof, A Basu, MT Redmond, AK Dobbs, L Perelygina, ... Pediatric blood & cancer 70 (5), e30183, 2022 | 3 | 2022 |
| Harnessing patient-specific response dynamics to optimize evolutionary therapies for metastatic clear cell renal cell carcinoma–Learning to adapt IC Sorribes, A Basu, R Brady, PM Enriquez-Navas, X Feng, JN Kather, ... biorxiv, 563130, 2019 | 3 | 2019 |
| Multimodal approaches to improve immunotherapy in breast cancer A Basu, K Kodumudi Immunotherapy 12 (3), 161-165, 2020 | 2 | 2020 |
| Strategies to Combat Human Epidermal Growth Factor Receptor 2 (HER2) Resistance in HER2-Positive Breast Cancer N Rajarajan, V Mariotti, A Basu, K Kodumudi, H Han, B Czerniecki, ... Critical Reviews™ in Oncogenesis 25 (3), 2020 | 2 | 2020 |
| ATAXIA-telangiectasia with compound heterozygous ATM mutations discovered on abnormal newborn screen ASE Lee, RS Abraham, A Basu, H Lederman, C Cunningham-Rundles Clinical Immunology, 110294, 2024 | 1 | 2024 |
| Th1 cytokines promotes E3 ubiquitin ligase Cullin 5 expression via STAT1 signaling cascade and enhance cul5 mediated proteasomal degradation of HER2 in HER2+/ER-breast cancer Y Jia, G Ramamoorthi, K Kodumudi, A Basu, D Wiener, B Czerniecki Cancer Research 79 (13_Supplement), 4434-4434, 2019 | 1 | 2019 |
| Antitumor efficacy of Type I polarized dendritic cells in combination with immune checkpoint blockade in a preclinical model of breast cancer KN Kodumudi, D Wiener, A Basu, B Czerniecki Cancer Research 78 (13_Supplement), 2545-2545, 2018 | 1 | 2018 |
| Expanding the diagnostic toolbox for complex genetic immune disorders ED Abrams, A Basu, MEZ Thomas, SE Henrickson, RS Abraham Journal of Allergy and Clinical Immunology, 2024 | | 2024 |
